Histone deacetylase (HDAC) Inhibitors - Pipeline Insight, 2024

This “Histone deacetylase (HDAC) Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Histone deacetylase (HDAC) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Histone deacetylase (HDAC) Inhibitors Understanding

Histone deacetylase (HDAC) Inhibitors: Overview

The histone deacetylase inhibitors (HDACi) are a group of small molecules that target histone deacetylases (HDACs) by inhibiting their activity. HDACi have a long history of use in neurology and psychiatry as antiepileptics and mood stabilizers. More recently, they have been investigated as possible treatments for cancer. Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Eighteen human HDAC enzymes have been identified and classified into four groups based on their homology with yeast HDACs.

• The acetylation of histones by HAT changes their charge from positive to negative, which reduces their interaction with negatively-charged DNA. This increases accessibility for the transcriptional machinery, resulting in transcriptional activation. This series of the events can be reversed by deacetylation by HDACs. Epigenetic changes caused by imbalances between HATs and HDACs can affect global transcriptional profiles.
• HDACs are so-named because they were first identified as enzymes that function to remove acetyl groups from lysine residues on the N-terminal tails of histones. However, recent phylogenetic studies suggest that all four classes of HDACs preceded the evolution of histone proteins, indicating that the primary substrates of HDAC enzymes are not histone proteins but non-histone proteins.
• HDACs are both directly and indirectly involved in many biological processes, including development, proliferation, differentiation, and cell death.

Histone deacetylase (HDAC) Inhibitors Emerging Drugs Chapters

This segment of the Histone deacetylase (HDAC) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Histone deacetylase (HDAC) Inhibitors Emerging Drugs

Givinostat: ItalfarmacoGivinostat is an investigational drug discovered through Italfarmaco’s internal research and development efforts in collaboration with Lorenzo Puri (SanfordBurnhamPrebys Medical Research Institute, San Diego, formerly Santa Lucia Foundation, Rome) and his team, and partnerships with Telethon and Parent Project aps. It is being evaluated for safety and efficacy for the treatment of Duchenne- and Becker- Muscular Dystrophy. Givinostat inhibits histone deacetylases (HDACs). HDACs are enzymes that prevent gene translation by changing the three-dimensional folding of DNA in the cell. Studies show that Duchenne patients have higher than normal HDAC levels, which may prevent muscle regeneration, and also trigger inflammation. In the company’s clinical study in DMD boys aged seven to less than 11 years, Givinostat was observed to slow disease progression, significantly increase muscle mass and reduce the amount of fibrotic tissue. Givinostat treatment also significantly reduced muscle tissue necrosis and fatty replacement, two additional parameters related to disease progression (Bettica et al., Neuromuscular Disorder 2016).

Histone deacetylase (HDAC) Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Histone deacetylase (HDAC) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Histone deacetylase (HDAC) Inhibitors

There are approx. 50+ key companies which are developing the Histone deacetylase (HDAC) Inhibitors. The companies which have their Histone deacetylase (HDAC) Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Italfarmaco.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Histone deacetylase (HDAC) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Histone deacetylase (HDAC) Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Histone deacetylase (HDAC) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Histone deacetylase (HDAC) Inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Histone deacetylase (HDAC) Inhibitors R&D. The therapies under development are focused on novel approaches for Histone deacetylase (HDAC) Inhibitors.

April 2020: Onxeo announced that it had entered into agreements (“the Agreements”) with Acrotech Biopharma which extend Acrotech’s rights to belinostat, to all territories not previously covered under Onxeo’s prior agreement with Acrotech as well as transfer certain IP and know-how related to belinostat in all its forms. Onxeo would receive a one-time payment of $6.6 million from Acrotech in exchange for these rights. Belinostat is currently marketed in the U.S. under the name Beleodaq (belinostat for injection) in the second-line treatment of patients with peripheral T cell lymphoma.

Histone deacetylase (HDAC) Inhibitors Report Insights

• Histone deacetylase (HDAC) Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Histone deacetylase (HDAC) Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Histone deacetylase (HDAC) Inhibitors drugs?
• How many Histone deacetylase (HDAC) Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Histone deacetylase (HDAC) Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Histone deacetylase (HDAC) Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Histone deacetylase (HDAC) Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Roche
• Takeda San Diego
• Italfarmaco
• Sulfidris
• MethylGene
• EpiGen Pharmaceuticals
• DAC Research
• Karus Therapeutics
• Xynomic Pharmaceuticals
• Medivir
• Mirati Therapeutics
• Janssen Pharmaceutica

Key Products

Research programme: histone deacetylase inhibitors- ACS 33

• MG 4915
• AP CANC04
• DAC 0060
• KAR 2581
• Abexinostat
• Remetinostat
• Mocetinostat
• Quisinostat

This product will be delivered within 1-3 business days.